New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team

SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity" has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and his orthodontic team, introduces a transformative diagnostic framework. Building upon the traditional Angle classification system categorizes and refines the clinical classification of malocclusions with additional diagnostic elements such as mandibular position and morphology, depth of curve of Spee and TMJ status, enabling more precise diagnostics and empowering clinicians to develop optimized treatment strategies.

Professor Gang Shen, the lead author of the paper, serves as the Chief Scientist of GS Technology (Mandibular Advancement Repositioning Technology) at Smartee Denti-Technology.

Redefining Diagnosis for Complex Malocclusions

For over a century, the Angle classification system has focused primarily on molar relationships. Professor Shen's research expands this scope by integrating facial appearance, mandibular position and morphology, depth of curve of Spee, and temporomandibular joint (TMJ) health into a comprehensive diagnostic system.

In the article, Professor Shen's team investigates the etiopathogenic mechanisms underlying distinct facial convexity subtypes and proposes evidence-informed, and subtype-specific treatment strategies. The research focuses on the clinical indications, biomechanical principles, and standardized operational protocols of mandibular advancement technology.

The paper explicitly states that leveling the occlusal curve is a critical prerequisite for achieving the desired mandibular repositioning effect. Furthermore, the paper emphasizes that the necessity of tooth extraction should be scientifically evaluated based on refined diagnostic classification, providing clinicians with a robust, evidence-based framework for clinical decision-making.

A New Perspective: Mandibular Morphology Analysis and Risk Assessment

A significant innovation presented in the study is "Mandibular Morphology Analysis," a diagnostic perspective with substantial clinical implications. By systematically evaluating the overall contour of the mandibular body and the degree of symphyseal concavity through lateral cephalograms, the research identifies two primary mandibular morphologies:

• Flat-Rectangular Mandible: Frequently observed in dentoalveolar facial convexity or cases involving mandibular retrusion. These patients typically present a "three-depth" bite pattern (deep overbite, deep overjet, and deep curve of Spee) and are considered ideal candidates for mandibular advancement therapy.

• Thick-Triangular Mandible: Common in skeletal facial convexity. This morphology is often associated with higher susceptibility of the temporomandibular joint (TMJ), where condylar resorption and mandibular retrusion are more frequently observed.

Theoretical Foundation for GS Technology and S8-SGTB

The classification system serves as the foundation and rationale for Mandibular Advancement Repositioning Technology (MART). As the digital implementation of this clinical wisdom, Smartee's GS product line provides standardized solutions for complex jaw discrepancies. The S8-SGTB, a specialized appliance within the GS product line mentioned in the research, is designed specifically for treating facial convexity with "three-depth" bite pattern.

Radiographic follow-up data in the study indicate that MART, when implemented via systems such as the S8-SGTB, can facilitate adaptive TMJ remodeling. This provides a viable, non-surgical alternative for achieving sustainable mandibular repositioning even in adult patients.

"This classification system bridges the gap between initial diagnosis, treatment planning, and long-term clinical outcomes," said Professor Gang Shen. "By identifying specific mandibular morphologies, practitioners can make more informed decisions between conventional extraction therapies and mandibular advancement repositioning."

About Smartee Denti-Technology

Founded in 2004, Smartee is the leading provider of clear aligners and digital orthodontic solutions in China. Headquartered in Shanghai, Smartee has four research & development centers and four manufacturing bases in China and Spain. By serving over 99,000 doctors in over 57 countries, Smartee has launched over 10 aligner products catering to different malocclusion problems for children, adolescents and adults. 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team

HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition from technical validation to large-scale commercialization, with annual revenue reaching RMB 164 million, a year-on-year increase of 133.7%.

Driven by the rapid adoption of its proprietary iMedImage^® foundation model, Diagens saw its technology licensing revenue soar by 331.7% to RMB 84.34 million, officially becoming the company's primary growth engine. Gross profit reached RMB 118 million, with a robust margin of 71.8%, reflecting a high-value business model built on "Model-as-a-Service" (MaaS).

The Industrialization of Medical AI: From "Bespoke Projects" to "Mass Production"

The medical imaging sector accounts for approximately 80% of global clinical data, yet traditional AI has long struggled with "point solutions"—developing one model for one disease in a single modality. This fragmented approach results in long R&D cycles and high costs, covering only a tiny fraction of the thousands of potential clinical applications.

Diagens is disrupting this legacy paradigm. Its iMedImage^® foundation model, boasting 104 billion parameters, covers 19 imaging modalities and 26 clinical specialties. By providing a standardized technological bedrock, Diagens has reduced the cost and time of developing high-quality specialized models by over 90%.

"We are witnessing a systemic restructuring of clinical capabilities," said a representative of Diagens' cross-disciplinary expert team, which comprises veterans from basic medicine, clinical practice, and advanced AI. "Our goal is to break the cost-efficiency barrier of medical AI, moving from 'craftsman-style' development to an industrial-scale deployment that can fill the widening global gap in healthcare resources."

MaaS Ecosystem: Accelerating Global Healthcare Infrastructure

Within just six months of launching the iMed MaaS^® (Model-as-a-Service) platform in 2025, Diagens partnered with 65 top-tier hospitals to incubate 92 specialized models. This ecosystem allows healthcare institutions to rapidly deploy AI capabilities tailored to specific clinical needs, effectively turning sophisticated diagnostic expertise into a scalable digital utility.

Diagens' reach now extends to over 400 medical institutions across China, including adoption by 40% of the nation's top ten hospitals. Beyond China, the company is positioning itself as a global healthcare AI infrastructure provider, aiming to lower the threshold for high-quality diagnostics worldwide.

Strategic Outlook: Scaling the New Productive Force

Looking ahead, Diagens plans to deepen its strategic collaboration with ecosystem partners, including technology giants like Tencent, to build a "Device + Service + Data" hub. By integrating the iMedImage^® foundation model into the global healthcare value chain, Diagens seeks to address the existential challenges of aging populations and physician shortages.

"This is not just a leap in tool efficiency; it is a fundamental shift in how medical services are produced and delivered," stated Dr. Ning Song, Chairman of Diagens. "Standing at this historical inflection point, we are committed to working with global stakeholders to ensure that truly clinical-grade AI is accessible, reliable, and safe for every patient, everywhere."

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine